Identification | Back Directory | [Name]
NMS-P626 | [CAS]
942471-37-6 | [Synonyms]
NMS-P626 Benzamide, N-[5-[(3,5-difluorophenyl)sulfonyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-[[(1R)-2-methoxy-1-methylethyl]amino]-4-(4-methyl-1-piperazinyl)- | [Molecular Formula]
C28H35F2N7O4S | [MOL File]
942471-37-6.mol | [Molecular Weight]
603.69 |
Hazard Information | Back Directory | [Uses]
NMS-P626 is an inhibitor of TRKA, TRKB, and TRKC, with IC50 values of 8 nM, 7 nM, and 3 nM, respectively. NMS-P626 inhibits the growth of KM12 cells by suppressing the phosphorylation of TPM3-TRKA and downstream signaling in KM12 cells, with an IC50 of 19 nM for KM12 cells. NMS-P626 can be used in colorectal cancer research[1]. | [IC 50]
TrkA: 8 nM (IC50); TrkB: 3 nM (IC50); TrkC: 7 nM (IC50) | [References]
[1] Ardini E, et al. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol. 2014 Dec;8(8):1495-507. DOI:10.1016/j.molonc.2014.06.001 |
|
|